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Summary 
Studies in vitro have suggested that  a species barrier exists in functional interaction between 
human histocompatibility leukocyte antigen (HLA) class II and mouse CD4 molecules. However, 
whether mouse CD4 + T  cells restricted by HLA class II molecules are generated in HLA class 
II transgenic mice and respond to peptide antigens across this barrier has remained unclear. In an 
analysis of T cell responses to synthetic peptides in mice transgenic for HLA-DR51 and - DQ6, 
we found that DR51 and DQ6 transgenic mice acquired significant T cell response to influenza 
hemagglutinin-derived peptide 30%319 (HA 307) and Streptococcus  pyogenes M12 protein-derived 
peptide 347-397 (M6C2), respectively. Inhibition studies with several monoclonal antibodies showed 
that  transgenic  HLA  class  II  molecules  presented  these  peptides  to  mouse  CD4 +  T  cells. 
Furthermore, T cell lines specific for HA 307 or M6C2 obtained from the transgenic mice could 
respond to the peptide in the context of relevant HLA class  II molecules expressed on mouse 
L  cell transfectants  that  lack  the expression of mouse MHC class  II.  These findings  indicate 
that  interaction  between HLA class  II and mouse CD4 molecules is sufficient for provoking 
peptide-specific HLA class  II-restricted  T  cell responses in  HLA class  II transgenic  mice. 
I 
nteraction of the CD4 coreceptor with class II products 
. of the MHC has  a critical role in intrathymic  selection 
(1, 2) and peripheral  immune response to foreign antigens 
of CD4 + T  cells  (3).  The CD4 molecule binds to the 82 
domain of the MHC class II molecule (4, 5) and provokes 
T cell responses by increasing avidity of T cell-APC interac- 
tion and/or by transmitting an intraceUular activation signal 
(6, 7). Although human (HLA) and mouse (H-2) MHC have 
evolved from common ancestral  genes (8), several studies sug- 
gest that a species barrier exists in functional interaction be- 
tween mouse CD4  and  human  class  II molecules in vitro 
(9-11). Lamarre et al. (9) considered the possibility that mouse 
CD4 probably did not interact with the HLA-DP molecule 
by analyzing the response of CD4- CD8- T cell hybridoma. 
Vignali  et  al.  (10)  showed  that  the  responses  of mouse 
CD4 § T cells to peptide antigens were reduced by replacing 
the 82 domain of the I-A molecule on APC with that  of 
the DR molecule. Furthermore,  T  cells from human CD4 
transgenic mice have been shown to respond to human class 
II molecules in a xenogeneic MLR stronger than that from 
normal mice (11). However, it has remained unclear whether 
mouse CD4 § T cells restricted by human class II molecules 
are generated in HLA class II transgenic mice and respond 
to foreign peptide antigen across this barrier. It is, therefore, 
essential to clarify this issue if we want to employ the HLA 
class  II transgenic  mice for investigating  the role of HLA 
class II in regulating immune response and disease suscepti- 
bility. 
We generated  transgenic  C57BL/6  (B6)  mice carrying 
genes for  both  HLA-DQ6A  (DQAI*0103)  and  -DQ6B 
(DQBI*0601) encoding ol and 8  chains of the HLA-DQ6 
molecule, respectively (DQ6-B6) (12), that for HLA-DRA 
(DRA*0101) encoding the monomorphic a  chain of the HLA- 
DR molecule (DRA-B6)  (13),  and  that  for HLA-DR51B 
(DRBS*0102) encoding the 8  chain of HLA-DR51 mole- 
cule (DR51B-B6). Here we show that DQ6-B6 and DR51- 
B6 obtained by crossing DR51B-B6 with DRA-B6 acquired 
peptide-specific, HLA-restricted T  cell responses,  and that 
functional interaction between HLA class II and mouse CD4 
molecules was involved in these responses. 
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Mice.  DRA-B6 and DQ6-B6 were generated and characterized 
as previously described (12, 13). DR51B-B6 were produced by in- 
jection of B6 oocytes with a 5.6-kb ApaI/EcoRI fragment con- 
taining the HLA-DR51B (DILB*0102) cDNA (14). This transgene 
includes a 4.0-kb ApaI/SacI fragment containing the 5' upstream 
region of DR51B gene and connected to the SV40 poly A signal 
sequence at the 3' side. Mice carrying the transgene were identified 
by Southern blot analysis using DR51B cDNA as a probe. DR51- 
B6 were obtained by crossing DRA-B6 with DR51B-B6. 
Reverse Transc@tase-PCR Analysis.  Total cellular RNA was ex- 
tracted from homogenized tissues or single cell suspensions, cDNA 
were made from RNA extracts digested by DNase I to avoid con- 
taminating transgenic DNA and were then subjected to PCR to 
amplify the DR51B for A~  b gene. The primers used were (5'- 
CACTGATGGTGCTGAGCTCCCCAC-3')  and  (5'-CCAAGG- 
AAGAGCAGGCCCAGCAC-3') for DR51B, and (5'-CGAAAG- 
GCATTTCGTGTACCAG-Y)  and  (5'-ATGCTAGACTCTGAG- 
TCGGAG-Y) for A3 b. PCR products were electrophoresed in a 
1.2% agarose gel, transferred onto a nylon membrane, and hybrid- 
ized with end-labeled oligonucleotide probes for DR51B (5'-GAG- 
TGTCATTTCTTCAACG-Y) and A3 b (5'-CGGCGGCTTGAA- 
CAGCCCA-Y)  as described (15). 
Flow Cytometry.  Cell surface expressions of HLA-DR51 mole- 
cules on B cells, dendritic cells, and macrophages were examined 
by flow cytometry (FCM)  1 as follows. Spleen cells from each strain 
of mice were cultured with II.-4 (50 U/ml) for 48 h and then doubly 
stained  with biotinylated goat anti-mouse IgG plus IgM (Tago, 
Inc., Burlingame, CA) followed by streptavidin-coupled PE, and 
TALl6.1, specific for HLA-DR51 (16), followed by FITC-conjugated 
goat anti-mouse IgG (Jackson ImmunoResearch, West Grove, PA). 
IgG plus IgM positive cells were gated to be analyzed as B cells. 
Splenic dendritic cells were prepared as described (17) and stained 
with TALl6.1. About 70-80% of cells prepared were positive for 
splenic dendritic cell marker 33D1 (18). Dish adherent spleen cells 
were prepared and cultured with IFN-y (250 U/ml) for 48 h, and 
then doubly stained with M1/70HL, specific for MAC-1  antigen 
expressed on macrophages (Hybritech, Inc., San Diego, CA) and 
TALl6.1. MAC-1 positive cells were gated to be analyzed as splenic 
macrophages.  All the cells expressed a comparable level of the I-A  b 
molecule. For analysis of the expression of DRc~E3  b molecules in 
DRA-B6 and DR51-B6, spleen cells were stained with biotinylated 
17-3-3, mAb specific for E3  b (19), followed by streptavidin-coupled 
PE. FCM was done by FACScan  |  (Becton Dickinson & Co., Moun- 
tain View,  CA). 
T Cell Proliferation Assays and Blocking Experiments.  Mice were 
immunized by giving 0.2 ml of soluble  HA 307 peptide (20/~g, 
PKYVKQNTLKLAT) or M6C2 peptide (20/zg, AKKQVEKD- 
LANLTAELDKVKE) emulsified  with CFA (Difco, Detroit, MI) 
into the hind footpads and at the base of the tail. These peptides 
were synthesized by a peptide synthesizer (model 9050 Plus; Milli- 
pore Corp., Bedford, MA) and purified by reversed-phase HPLC. 
Popliteal and inguinal lymph nodes were removed 9-12 d later and 
single cell suspensions were prepared in RPMI 1640 medium (Gibco 
BRL, Gaithersburg, MD) supplemented with 10% heat-inactivated 
FCS, 100 U/ml penicillin,  100/zg/ml streptomycin, 2 mM I.-glu- 
tamine, 50 #M 2-ME, and 20 mM Hepes (complete medium). To 
purify lymph node cells to T  cells, I-A  b positive cells were elimi- 
nated by using sheep anti-mouse IgG coated magnetic beads (Dynal, 
1 Abbreviation used in this paper: FCM, flow cytometry. 
Oslo,  Norway) and anti-LA  b mAb  (Meiji,  Odawara, Japan)  as 
follows. Magnetic beads were added to the cell suspension and the 
preparation was centrifuged for 10 min at 1,500 rpm followed by 
resuspension  of the cells and removal of the beads/IgG positive B 
cells. This step was repeated twice and cell suspensions were subse- 
quently incubated with anti-LA  b mAb at a saturating concentra- 
tion for 30 min at 4~  The cells were then washed three times 
with complete medium and further enriched to T cells using mag- 
netic beads. The enriched T cells (4  x  10  s) were cultured in 0.2 
ml of complete medium in triplicate in 96-well flat-bottom tissue 
culture plates, containing 8  x  10  s irradiated  (3,000 rad) syngeneic 
spleen cells as APCs in the presence or absence of antigen peptide 
at 37~  in a humidified atmosphere of 5% CO2 for 48 h. I #Ci 
of [3H]thymidine  was added during the final 12 h and then incor- 
porated radioactivity was measured. In blocking experiments on 
the T  cell responses  with mAbs,  a 200-fold diluted ascites form 
of anti-Lyt2.2  (anti-CD8; Meiji), 3JP (anti-Aoe  b) (20), HUll (anti- 
DQ) (21), or a fourfold diluted culture supernatant GK1.5 (anti- 
CD4) (22), or 1.3 #g/ml purified L243 (anti-DR) (23), or 10 #g/ml 
purified 17-3-3 (anti-E3b),  17/227 (anti-A3  b) (24), 20-8-4S (anti- 
KbD  b) (25) was added  to the culture. 
Antigen-specific T Cell Line.  T cells were purified from lymph 
node cells of DR51-B6 or DQ6-B6 preimmunized with 20 #g of 
peptide  by  eliminating  I-A  b positive  cells  as  described  above. 
Purified T cells (6  x  106) were cultured with 25  x  106 irradiated 
(3,000 rad) syngeneic spleen cells with HA 307 or M6C2 peptide 
at 10 #g/ml in complete medium for 5 d. Viable cells were col- 
lected by density  gradient  centrifugation  with  Lympholyte-M 
(Cedarlane Laboratories,  Hornby, ON, Canada) and further cul- 
tured without stimulator cells and antigen for 5 d. The stimula- 
tion and resting cycle was repeated twice in medium supplemented 
with rat Con A supernatant (Becton Dickinson & Co.). A T cell 
line (5  x  104) was cultured with 3  x  104 indicated mouse L cell 
transfectants  pretreated with mitomycin C in the presence or ab- 
sence  of peptide for 36  h.  1 /zCi  of [3Hlthymidine was  added 
during  the  final  6  h  and  then  incorporated radioactivity was 
measured. 
Results and Discussion 
We previously reported that HLA-DQ6  molecules were 
expressed in the thymus, lungs, lymph nodes, and spleen in 
a tissue-specific manner as was MHC class II in DQ6-B6 (12). 
In DR51-B6 obtained by crossing DR51B-B6 with DRA- 
B6, the DR51B transgene was expressed in the thymus, spleen, 
and lung (Fig. 1 A). This suggested that HLA-DR51 mole- 
cules were expressed on various immunocompetent cells such 
as thymic epithelial cells, B cells, macrophages, and dendritic 
cells in DR51-B6  because DRA-B6  expressed DRoe chain 
as DRoLE3  b molecule on these cells (13).  Cell surface expres- 
sions of DR51  molecules on these immunocompetent cells 
were confirmed by FCM analysis (Fig. 1 B). It should be noted 
that DR51-B6 also expresses a xenogeneic mixed isotype mol- 
ecule, DRo~E3 b, as in DRA-B6 (Fig. 2). Expression of the 
DRc~A3 b molecule in DRo~ single transgenic mice was not 
demonstrated  by  immunoprecipitation  (26)  nor  was  the 
Ao~bDR51t5 molecule in DR51B-B6 demonstrated by FCM 
using anti-DR3 polyclonal antibody (data not shown). Thus, 
DR51-B6 apparently expresses three different MHC class  II 
molecules, DR51,  DRczE3b, ' and I-AL In DQ6-B6,  mixed 
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gene in transgenic HLA-DR51 C57BL/6 mice 
(DR51-B6).  (A)  Reverse transcriptase-PCR 
analysis of DR51B and I-A/~  b gene transcripts 
in various organs in DR51-B6 or in cell lines. 
(/3) Cell surface expression of the DR51 mole- 
cule  on B cells, splenic dendritic  cells, and 
splenic  macrophages of B6, DRA-B6, DR51B- 
B6, and DR51-B6  (shaded). The background 
stainings for each sample is presented in the 
same panel (unshaded). 
isotype molecules were not detected by immunoprecipita- 
tion (12). 
In a previous study (12), it was shown that DQ6-B6 did 
not produce antibodies specific for the DQ6 molecule, and 
that loss of MLR against the DQ6 molecule was observed 
in DQ6-B6, suggesting that DQ6-B6 acquired a tolerance 
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Figure 2.  Cell surface expression of the DRoeE3 b molecule on spleen 
cells of DRA-B6 and DR51-B6  (shaded). The background stainings for 
each sample is presented in the same panel (unshaded). 
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to HLA-DQ6 molecule at the B and T cell levels. To investi- 
gate whether DR51-B6 acquired  a tolerance  to the HLA-DR51 
molecule, mice were immunized with the EBV-transformed 
human B cell line, TOK, which expresses HLA-DR51 mol- 
ecules, and the production of antibodies specific for DR51 
molecule was examined. As expected, DR51-B6 did not pro- 
duce antibodies against DR51 molecule, whereas B6, DRA- 
B6, and DR51B-B6 produced the antibodies (data not shown). 
In addition,  a primary MLR using DR51-B6 spleen cells as 
stimulator showed that the transgenic DR51 molecule could 
stimulate T  cells from B6, DRA-B6, and DR51B-B6,  but 
not DR51-B6 (data not shown). These findings indicate that 
DR51-B6  acquired a tolerance to transgene products as had 
DQ6-B6, suggesting that transgenic HLA class II molecules 
contributed to eliminate  self-reactive T  cells as had MHC 
class II molecules. 
Next, in order to examine whether HLA class II mole- 
cules expressed in mice would provoke T  cell responses to 
foreign peptide antigens, mice were immunized  with influenza 
A hemagglutinin-derived  peptide 307-319 (HA 307), known 
to be a satisfactory DR binding peptide (27), or with Strep- 
tococcuspyogenes  M12 protein-derived peptide 347-367 (M6C2), A 
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Figure 3.  Immune  responses to peptide antigens in HLA transgenic mice. DR51-B6 and DQ6-B6 acquired  the T cell response  to HA 307 peptide 
(A) and M6C2 peptide (B), respectively.  Anti-CD4 but not anti-CD8 mAb inhibited these T cell responses (C and D), Data presented  are representative 
of three experiments and are expressed as the mean -+  SD of triplicate wells. 
which is a DQ6-restricted antigenic peptide in humans (28), 
and secondary proliferative T cell responses in vitro were mea- 
sured. Fig. 3 A  shows that DR51-B6 acquired the T cell re- 
sponse to HA 307, whereas no proliferative response was ob- 
served in B6, DRA-B6, or DR51B-B6. On the other hand, 
the immune response to M6C2 was observed only in DQ6- 
B6 (Fig.  3 B). DR51-B6 and DQ6-B6 did not acquire the 
T cell response to M6C2 and HA 307, respectively (data not 
shown). Anti~  but not anti-CD8 mAb inhibited these 
responses (Fig. 3, C  and D). These results suggest that the 
DR51 molecule, but not DRotE3  b or I-A  b, presented HA 
307 to mouse CD4 + T cells in DR51-B6, whereas the DQ6 
molecule presented M6C2  to CD4 §  T  cells  in DQ6-B6. 
However, it remained to be determined whether functional 
interaction of mouse CD4 with HLA class II molecules was 
involved in these responses, because mouse CD4 might in- 
teract with the/3 chain of DRc~E3  b and/or I-A  b expressed 
in addition to DR51 or DQ6 molecules on the same APC 
(9,  12). 
To clarify this point,  inhibitory effects by several mAbs 
specific for mouse MHC class II molecules on the T cell re- 
sponses  were examined. As shown in Fig. 4, mAbs specific 
for E3  b (17-3-3),  which are known to react with DRotE3  b 
(13,  29) or those for A3  b (17/227), failed to block the re- 
sponses  as well as had anti-Act  b (3JP).  By contrast, the re- 
sponse was completely inhibited by anti-DR (L243) in DR51- 
B6 and anti-DQ (HUll) in DQ6-B6. These results suggest 
that the DRotE3  b or I-A  b molecules did not play a major 
role in these responses. 
To examine more closely the interaction of mouse CD4 
with HLA class II, CD4 + T  cell lines specific for HA 307 
or M6C2 were obtained from DR51-B6 or DQ6-B6, respec- 
tively, and their restriction elements were investigated using 
mouse L cells transfected with various HLA class II as APCs 
that do not express endogenous mouse MHC class II mole- 
cules. Consistent with the blocking experiments, each T cell 
line specific for either HA 307 or M6C2 responded to the 
peptide antigen in the context of the relevant HLA class II 
molecules in the absence of mouse class II (Fig.  5, A  and 
B). These responses were restricted to DR51 or DQ6 mole- 
cules because the L cells expressing each of the DR1, DR2, 
or DR4 molecules, which are known to present HA 307 to 
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Figure  4.  Effects  of antibodies specific  for 
various MHC molecules  on T cell  response  in 
HLA transgenic mice. (A) Response to HA 
307 in DR51-B6 and (B) that to M6C2 in 
DQ6-B6. Peptides were used at a concentra- 
tion of I/~g/ml. Data presented are represen- 
tative of three experiments and are expressed 
as the mean +_ SD of triplicate wells. 
human T cells (27), and those expressing DQ4, which binds 
M6C2 (data not shown), could not present the antigen pep- 
tides to these T  cell lines. 
Spleen cells from bone marrow chimera-B6 and -DRA- 
B6,  which were reconstituted with DR51-B6  BM, could 
stimulate the HA 307-specific DR51-restricted T  cell line, 
but these bone marrow chimera mice did not acquire the T 
cell response to HA 307  (data not shown). These observa- 
tions indicate that the responding T  cells observed  in the 
DK51-B6 express TCR antigens that were selected positively 
in the thymus by the transgene product, but not by I-A  b or 
DR(xEB  b molecules. Previous study (2) has shown that in- 
teraction of CD4 with MHC class II molecules is critical 
for the generation of MHC class II-restricted mature T cells 
by analyzing T  cell differentiation in CD4-deficient mice. 
Taken  together, we conclude that HLA class II-restricted 
mouse CD4 + T  cells were generated by significant interac- 
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tion between HLA class II and mouse CD4 molecules in the 
thymus of the transgenic mice, and that these cells could recog- 
nize antigen peptides in the context of HLA class II molecules. 
Our results would contradict the previous observations 
showing that a species barrier exists in functional interaction 
between HLA class II and mouse CD4 molecules (9-11). How- 
ever, it has been also suggested that this barrier is partial and 
that CD4 can bind to the MHC class II (x chain or a con- 
served site that itself is not species specific (10, 30). We cannot 
assess in this study whether T cell responses in the HLA class 
II transgenic mice will be augmented by introducing human 
CD4, or whether a HLA class II transgenic mouse expressing 
chimeric human/mouse MHC class II molecules that con- 
tain  mouse  class  II-CD4  interacting region  will  acquire 
stronger T cell response than the transgenic mice used in this 
study. However, one prominent feature of this study was that 
we established  two strains of HLA class II transgenic mice A 
APC 
L-neo 
L-ORS1 
L-OR1 
L-DR2 
L-DR4 
HA 307  0 
[-, 
. 
[:" 
II 
H 
"i  E- 
+ 
H-Thymidine incorporation  (r  X 10  "3) 
10  20  30  40 
I  I  I  I  5O 
i 
B 
APC  M6C2 
[-  L-~o  * 
E- 
L-~  § 
L-DQ4 ~--§ 
0 
~H-Thymidlne  Incorporation  (cpmXl0  "~ ) 
10  2O  30 
i  I  l 
40 
I 
Figure  5.  Recognition of HA 307 and M6C2 
peptide in the context of the relevant HLA class 
II molecule expressed on the mouse L cell trans- 
fectant by T cell lines established from DR51-B6 
(.4) and DQ6-B6 (B), respectively.  Peptides were 
used at a concentration of 5 #g/ml. 98% ofT lym- 
phoblasts were positive for CD4. Data presented 
are representative of three experiments and are ex- 
pressed as the mean  _+  SD of triplicate wells. 
expressing HLA-DR  or -DQ molecules in a tissue-specific 
manner as MHC  class II and T  cell responses to peptide an- 
tigens were  analyzed in  an in vivo  system.  Therefore,  our 
observations indicate that interaction between HLA class II 
and mouse  CD4  molecules is physiologically sufficient for 
generating  HLA class II-restricted mouse T  cell repertoire 
and for provoking peptide-specific mouse T  cell responses. 
Thus, we propose that HLA class II transgenic mice can serve 
to investigate the role of HLA class II molecules in regulating 
immune responses  and  disease susceptibility  in  humans. 
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